VivoSim Labs (VIVS) Accumulated Expenses (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Accumulated Expenses of $422000.0 for Q1 2026, down 65.58% year-over-year from $1.2 million in Q1 2025, and down 48.41% quarter-over-quarter from $818000.0 in Q4 2025.
VivoSim Labs (VIVS) Accumulated Expenses (2011 - 2026) Analysis & Trends
VivoSim Labs' Accumulated Expenses history runs 16 years deep, the most recent figure standing at $422000.0 for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 65.58% year-over-year to $422000.0; the TTM figure through Mar 2026 stood at $422000.0 (down 65.58% YoY), while the FY2026 annual figure was $422000.0, down 65.58% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $422000.0, down from $818000.0 in the prior quarter.
- The five-year high for Accumulated Expenses was $1.2 million in Q1 2025, with the low at $229000.0 in Q3 2025.
- The 5-year median for Accumulated Expenses is $609000.0 (2023), against an average of $608882.4.
- The sharpest annual moves came in 2025 and 2026: Accumulated Expenses jumped 128.73% in 2025, then sank 65.58% in 2026.
- VivoSim Labs' Accumulated Expenses stood at $646000.0 in 2022, then rose by 12.54% to $727000.0 in 2023, then surged by 39.61% to $1.0 million in 2024, then declined by 19.41% to $818000.0 in 2025, then tumbled by 48.41% to $422000.0 in 2026.
- Business Quant data shows VIVS's Accumulated Expenses at $422000.0 in Q1 2026, $818000.0 in Q4 2025, and $229000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 738,000.00 |
| Mar 31, 2026 | 422,000.00 |
| Dec 31, 2025 | 818,000.00 |
| Sep 30, 2025 | 229,000.00 |
| Jun 30, 2025 | 727,000.00 |
| Mar 31, 2025 | 1.23 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 356,000.00 |
| Jun 30, 2024 | 404,000.00 |
| Mar 31, 2024 | 536,000.00 |
| Dec 31, 2023 | 727,000.00 |
| Sep 30, 2023 | 283,000.00 |
| Jun 30, 2023 | 787,000.00 |
| Mar 31, 2023 | 609,000.00 |
| Dec 31, 2022 | 646,000.00 |
| Sep 30, 2022 | 462,000.00 |
| Jun 30, 2022 | 670,000.00 |
| Mar 31, 2022 | 434,000.00 |
| Dec 31, 2021 | 926,000.00 |
| Sep 30, 2021 | 717,000.00 |